[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648247":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":11,"locations":26,"responsibleParty":108,"collaborators":11,"id":110,"slug":111,"hasResults":112,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":11,"eligibilityCriteria":116,"healthyVolunteers":112,"sex":117,"minAge":118,"maxAge":11,"enrollmentInfo":119,"targetDuration":11,"studyType":122,"phases":123,"briefSummary":126,"conditions":127,"keywords":11,"overallStatus":129,"whyStopped":11,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":139},{"fullName":5,"class":6},"Hutchmed","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Part A (Dose Escalation)","EXPERIMENTAL",null,[13],"Drug: HMPL-A830",{"label":15,"type":10,"description":11,"interventionNames":16},"Part B (Dose Optimization)",[13],[18,23],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","HMPL-A830","Enrolled participants with solid tumors will receive HMPL-A830 treatment in a dose escalation setting at 6\n\npredefined dose levels",[9],{"type":19,"name":20,"description":24,"armGroupLabels":25,"otherNames":11},"Participants will be randomized in a 1:1 ratio to receive treatment in two RDO levels. Randomization will be stratified by tumor types.",[15],[27,42,53,64,75,86,97],{"facility":28,"status":11,"city":29,"state":11,"zip":11,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Beijing Cancer Hospital","Beijing","China","CN",{"type":33,"coordinates":34},"Point",[35,36],116.39723,39.9075,{"lat":36,"lon":35},[39],{"name":40,"role":41,"phone":11,"phoneExt":11,"email":11},"Lin Shen","CONTACT",{"facility":43,"status":11,"city":44,"state":11,"zip":11,"country":30,"countryCode":31,"cosmosGeoPoint":45,"geoPoint":49,"contacts":50},"Hunan Cancer Hospital","Changsha",{"type":33,"coordinates":46},[47,48],112.97087,28.19874,{"lat":48,"lon":47},[51],{"name":52,"role":41,"phone":11,"phoneExt":11,"email":11},"Yongchang Zhang",{"facility":54,"status":11,"city":55,"state":11,"zip":11,"country":30,"countryCode":31,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"West China Hospital of Sichuan University","Chengdu",{"type":33,"coordinates":57},[58,59],104.06667,30.66667,{"lat":59,"lon":58},[62],{"name":63,"role":41,"phone":11,"phoneExt":11,"email":11},"Li Zheng",{"facility":65,"status":11,"city":66,"state":11,"zip":11,"country":30,"countryCode":31,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"The Sixth Affiliated Hospital,Sun Yat-sen University","Guangzhou",{"type":33,"coordinates":68},[69,70],113.25,23.11667,{"lat":70,"lon":69},[73],{"name":74,"role":41,"phone":11,"phoneExt":11,"email":11},"Yanhong Deng",{"facility":76,"status":11,"city":77,"state":11,"zip":11,"country":30,"countryCode":31,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"Shandong Cancer Hospital","Jinan",{"type":33,"coordinates":79},[80,81],116.99722,36.66833,{"lat":81,"lon":80},[84],{"name":85,"role":41,"phone":11,"phoneExt":11,"email":11},"shuqin Ni",{"facility":87,"status":11,"city":88,"state":11,"zip":11,"country":30,"countryCode":31,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"Jiangsu Province Hospital","Nanjing",{"type":33,"coordinates":90},[91,92],118.77778,32.06167,{"lat":92,"lon":91},[95],{"name":96,"role":41,"phone":11,"phoneExt":11,"email":11},"Xiaofeng Chen",{"facility":98,"status":11,"city":99,"state":11,"zip":11,"country":30,"countryCode":31,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"Shanxi Provincial Cancer Hospitial","Taiyuan",{"type":33,"coordinates":101},[102,103],112.56028,37.86944,{"lat":103,"lon":102},[106],{"name":107,"role":41,"phone":11,"phoneExt":11,"email":11},"Hongxia Lu",{"type":109,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100648247","phase-1-hmpl-a830-in-solid-tumors-100648247",false,"NCT07718581","HMPL-A830 in Solid Tumors","A Phase I\u002FⅡa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HMPL-A830 in Solid Tumors","Inclusion Criteria:\n\n1. Understood this study and are able to voluntarily sign the informed consent form (ICF);\n2. Male or Female, Age ≥ 18 years;\n3. Histological confirmed, unresectable, advanced or metastatic solid tumor\n4. Participants must have at least one measurable lesion per Response Evaluation Criteria in Solid Tumors(RECIST) v1.1\n5. Life expectancy ≥ 12 weeks\n6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1\n\nExclusion Criteria:\n\n1. Use strong inhibitors of cytochrome P450 3A4 enzyme (CYP3A4), and inhibitors of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) within 5 elimination half-lives or 2 weeks (whichever is longer) before the first dose of study drug\n2. Major surgery within 28 days prior to the first dose of study drug\n3. Active infection requiring systemic treatment\n4. History of inflammatory gastrointestinal diseases\n5. Known hypersensitivity to any component of HMPL-A830\n6. Pregnant (positive pregnancy test) or lactating;","ALL","18 Years",{"count":120,"type":121},147,"ESTIMATED","INTERVENTIONAL",[124,125],"PHASE1","PHASE2","This is a first-in-human (FIH), multicenter, open-label, phase I\u002FⅡa clinical study of HMPL-A830 in participants with histologically or cytologically confirmed, unresectable, advanced, or metastatic solid tumors\\*, who are refractory or progressed on\u002Fafter available standard treatment. The study will be conducted in 2 parts:\n\nDose Escalation (Part A, Phase I), approximately 57 participants will be enrolled.\n\nDose Optimization (Part B, Phase IIa), approximately 90 participants will be enrolled.",[128],"Solid Tumor, Adult","NOT_YET_RECRUITING","2026-07-17",{"date":132,"type":133},"2026-07-22","ACTUAL",{"date":135,"type":121},"2026-08-15",{"date":137,"type":121},"2028-11-26",{"name":5,"class":6},7]